Table 3.
Data on isavuconazole administration
| Variables | Patients N: 30 (%) |
|---|---|
| Dose | |
| Loading dose 200 mg 3 times daily for 2 days | 30 (100) |
| Maintenance dose 200 mg once daily | 30 (100) |
| Formulation | |
| Intravenous only | 10 (33) |
| Orally only | 10 (33) |
| Intravenous followed by orally | 10 (33) |
| Duration | |
| Overall duration, days mean (range) | 87.6 (1, 568) |
| Intravenous administration duration, days mean (range) | 12.2 (1, 127) |
| Oral administration duration, days mean (range) | 117.3 (1, 568) |
| Prior administration of other antifungal agentsa | 27 (90) |
| Posaconazole | 7 |
| Liposomal amphotericin-B | 6 |
| Fluconazole | 6 |
| Voriconazole | 2 |
| Echinocandin | 5 |
| No antifungal | 3 |
| Concomitant administration with other antifungal agents | 1 (3.3) |
| Neutropenia during IVC administration, days mean (range) | 18.8 (4, 30) |
| Indication for IVC administrationb | |
| Adverse events of prior treatment | 14(46.6) |
| Hepatotoxicity | 6 |
| Renal insufficiency | 4 |
| Long QTc interval | 3 |
| Central nervous system | 1 |
| Potential drug–drug interactions | 4 (13.3%) |
| Clinical efficacy | 5 (16.6) |
| Sub-therapeutic posaconazole level | 1 |
| Combination treatment | 4 |
| Otherc | 10 (33.3) |
| Indication for IVC discontinuationb | |
| Treatment completion | 5 (16.7) |
| Treatment de-escalation | 5 (16.7) |
| Adverse events | 5 (16.7) |
| Rash | 2 |
| Hepatotoxicity | 2 |
| Drug–drug interactions | 1 |
| Insurance coverage | 3 (10) |
| Death | 3 (10) |
| Disease progression | 3 (10) |
| Ongoingd | 3 (10) |
IVC Isavuconazole, IFI invasive fungal infection
aAdministration of other antifungal agents during the 30 days prior to isavuconazole administration. A patient could have received more than one antifungal agent prior to isavuconazole administration
bA patient could have more than one indication for isavuconazole administration and/or discontinuation
cOther reasons for initiation of treatment with isavuconazole included the following: (1) transition from intravenous to orally administered treatment in 5 patients, (2) treating team choice for two cases of probable pulmonary invasive aspergillosis and a patient with proven pulmonary and cerebral Rhizomucor pusillus mucormycosis, (3) no specific indication in two patients
dThree patients were still on isavuconazole at the end of the study period